Safety gains don't translate into reduced costs or increased QALYs for doxycycline compared with prednisolone for patients with bullous pemphigoid

Sach, Tracey ORCID: https://orcid.org/0000-0002-8098-9220 (2018) Safety gains don't translate into reduced costs or increased QALYs for doxycycline compared with prednisolone for patients with bullous pemphigoid. British Journal of Dermatology, 178 (2). pp. 320-321. ISSN 0007-0963

Full text not available from this repository. (Request a copy)

Item Type:	Article
Uncontrolled Keywords:	cost-benefit analysis,doxycycline,humans,pemphigoid, bullous,prednisolone,quality-adjusted life years
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Health Economics Faculty of Medicine and Health Sciences > Research Groups > Norwich Clinical Trials Unit Faculty of Medicine and Health Sciences > Research Groups > Public Health and Health Services Research (former - to 2023)
Depositing User:	LivePure Connector
Date Deposited:	16 Jul 2020 23:47
Last Modified:	22 Oct 2022 06:30
URI:	https://ueaeprints.uea.ac.uk/id/eprint/76154
DOI:	10.1111/bjd.16226

Actions (login required)

View Item